🟢 ACADIA Pharmaceuticals is trading 4.75% up in pre-market after European Commission grants DAYBU marketing authorization

ACADIA Pharmaceuticals is trading 4.75% up at $30.90 after the European Commission granted DAYBU marketing authorization for Rett syndrome symptoms in adults and children aged five and older.

• DAYBU is the first and only treatment authorized for Rett syndrome in the European Union.
• Trading is occurring before the August 24, 2026 regular-session open; no reliable pre-market volume data was identified.